David S Fedson

Summary

Country: France

Publications

  1. ncbi Commentary: From scarcity to abundance: pandemic vaccines and other agents for "have not" countries
    David S Fedson
    University College London, UK
    J Public Health Policy 28:322-40. 2007
  2. ncbi Treating influenza with statins and other immunomodulatory agents
    David S Fedson
    57, chemin du Lavoir, 01630 Sergy Haut, France Electronic address
    Antiviral Res 99:417-35. 2013
  3. pmc How to optimise the coverage rate of infant and adult immunisations in Europe
    Heinz J Schmitt
    Infectious Diseases Service at the Zentrum für Präventive Pädiatrie, Johannes Gutenberg Universitat, Mainz, Germany
    BMC Med 5:11. 2007
  4. ncbi Vaccine development for an imminent pandemic: why we should worry, what we must do
    David S Fedson
    Hum Vaccin 2:38-42. 2006
  5. ncbi Confronting an influenza pandemic with inexpensive generic agents: can it be done?
    David S Fedson
    Lancet Infect Dis 8:571-6. 2008
  6. ncbi NEW technologies for meeting the global demand for pandemic influenza vaccines
    David S Fedson
    Biologicals 36:346-9. 2008
  7. pmc Meeting the challenge of influenza pandemic preparedness in developing countries
    David S Fedson
    Emerg Infect Dis 15:365-71. 2009
  8. ncbi Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work
    David S Fedson
    Influenza Other Respir Viruses 3:129-42. 2009
  9. ncbi Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe
    David S Fedson
    57 Chemin du Lavoir, 01630 Sergy Haut, France
    Expert Rev Vaccines 10:1143-67. 2011
  10. ncbi Pandemic influenza: a potential role for statins in treatment and prophylaxis
    David S Fedson
    Clin Infect Dis 43:199-205. 2006

Collaborators

Detail Information

Publications24

  1. ncbi Commentary: From scarcity to abundance: pandemic vaccines and other agents for "have not" countries
    David S Fedson
    University College London, UK
    J Public Health Policy 28:322-40. 2007
    ..The "have not" countries must continue to put pressure on WHO and leading countries to ensure that they will have access to the interventions they will need...
  2. ncbi Treating influenza with statins and other immunomodulatory agents
    David S Fedson
    57, chemin du Lavoir, 01630 Sergy Haut, France Electronic address
    Antiviral Res 99:417-35. 2013
    ..Treatment with statins and other immunomodulatory agents represents a new approach to reducing mortality caused by seasonal and pandemic influenza...
  3. pmc How to optimise the coverage rate of infant and adult immunisations in Europe
    Heinz J Schmitt
    Infectious Diseases Service at the Zentrum für Präventive Pädiatrie, Johannes Gutenberg Universitat, Mainz, Germany
    BMC Med 5:11. 2007
    ..Although vaccination has been proved to be a safe, efficacious, and cost-effective intervention, immunisation rates remain suboptimal in many European countries, resulting in poor control of many vaccine-preventable diseases...
  4. ncbi Vaccine development for an imminent pandemic: why we should worry, what we must do
    David S Fedson
    Hum Vaccin 2:38-42. 2006
    ..Vaccination for an imminent pandemic requires a global perspective not only for vaccine development but also for vaccine production and distribution...
  5. ncbi Confronting an influenza pandemic with inexpensive generic agents: can it be done?
    David S Fedson
    Lancet Infect Dis 8:571-6. 2008
    ....
  6. ncbi NEW technologies for meeting the global demand for pandemic influenza vaccines
    David S Fedson
    Biologicals 36:346-9. 2008
    ..These technologies could help meet the global demand for pandemic vaccines, but only if they are coupled with improvements in the human infrastructure necessary for pandemic vaccination...
  7. pmc Meeting the challenge of influenza pandemic preparedness in developing countries
    David S Fedson
    Emerg Infect Dis 15:365-71. 2009
    ..Without this research, industrialized and developing countries could face an unprecedented health crisis...
  8. ncbi Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work
    David S Fedson
    Influenza Other Respir Viruses 3:129-42. 2009
    ..Research is urgently needed to determine whether these and other agents that modify the host response might be useful in managing H5N1 influenza and the next pandemic...
  9. ncbi Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe
    David S Fedson
    57 Chemin du Lavoir, 01630 Sergy Haut, France
    Expert Rev Vaccines 10:1143-67. 2011
    ....
  10. ncbi Pandemic influenza: a potential role for statins in treatment and prophylaxis
    David S Fedson
    Clin Infect Dis 43:199-205. 2006
    ..Generic statins will be widely distributed and inexpensive. They might be the only agents that could alter the course of a global pandemic...
  11. ncbi Preparing for pandemic vaccination: an international policy agenda for vaccine development
    David S Fedson
    J Public Health Policy 26:4-29. 2005
    ..Whether this international policy agenda for pandemic vaccine development will succeed is uncertain, but it will provide a good indication of whether "good governance" for global public health can be achieved...
  12. ncbi Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence
    David S Fedson
    Lancet Infect Dis 3:272-3; discussion 273-4. 2003
  13. ncbi Pandemic influenza and the global vaccine supply
    David S Fedson
    Clin Infect Dis 36:1552-61. 2003
    ....
  14. ncbi Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults
    David S Fedson
    Aventis Pasteur MSD, Lyon, France
    Vaccine 22:927-46. 2004
    ..This evidence is sufficient to justify wider use of pneumococcal vaccine...
  15. ncbi Vaccination for pandemic influenza and severe acute respiratory syndrome: common issues and concerns
    David S Fedson
    Clin Infect Dis 36:1562-3. 2003
  16. ncbi Pneumococcal vaccination in older adults
    David S Fedson
    N Engl J Med 349:712-4; author reply 712-4. 2003
  17. ncbi Vaccination for pandemic influenza: a six point agenda for interpandemic years
    David S Fedson
    Pasteur Merieux MSD, Sergy Haut, France
    Pediatr Infect Dis J 23:S74-7. 2004
    ..However, because most influenza vaccine (85%) is produced in only eight countries, adequate production and equitable distribution of vaccine throughout the world will pose a serious challenge when the next influenza pandemic appears...
  18. ncbi Interview with David S. Fedson, MD, Former Professor of Medicine, University of Virginia School of Medicine, and Director of Medical Affairs, Aventis Pasteur MSD by Madeline Drexler
    David S Fedson
    Biosecur Bioterror 3:9-15. 2005
  19. pmc Influenza vaccination: policy versus evidence: no gap between policy and evidence
    David S Fedson
    BMJ 333:1020. 2006
  20. ncbi Influenza and the winter increase in mortality in the United States, 1959-1999
    Thomas A Reichert
    Entropy Research Institute, 262 West Saddle River Road, Upper Saddle River, NJ 07458, USA
    Am J Epidemiol 160:492-502. 2004
    ..Weather and other factors may determine the timing and modulate the magnitude of the winter-season increase in mortality, but the primary determinant appears to be the influenza virus...
  21. ncbi Statins and the risk of pneumonia: a population-based, nested case-control study
    Raymond G Schlienger
    Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Pharmacotherapy 27:325-32. 2007
    ..To determine if the use of statins affects pneumonia-related outpatient visits, hospitalizations with survival, and deaths...
  22. ncbi The conjugate vaccine and invasive pneumococcal disease
    David S Fedson
    N Engl J Med 349:714-6; author reply 714-6. 2003
  23. ncbi Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study
    Angela Dominguez
    Department of Health, Generalitat of Catalonia, Barcelona, Spain
    Clin Infect Dis 40:1250-7. 2005
    ..We evaluated the effectiveness of a 23-valent pneumococcal vaccination program for elderly people in Catalonia, Spain, in a matched-set case-control study...
  24. ncbi Statin protection against influenza and COPD mortality
    David S Fedson
    Chest 132:1406; author reply 1406-7. 2007